These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 31321712)
41. Identification of a four-gene metabolic signature predicting overall survival for hepatocellular carcinoma. Liu GM; Xie WX; Zhang CY; Xu JW J Cell Physiol; 2020 Feb; 235(2):1624-1636. PubMed ID: 31309563 [TBL] [Abstract][Full Text] [Related]
42. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma. Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y Front Immunol; 2022; 13():994019. PubMed ID: 36177006 [TBL] [Abstract][Full Text] [Related]
43. Integrative analysis of DNA methylation and gene expression identify a six epigenetic driver signature for predicting prognosis in hepatocellular carcinoma. Li GX; Ding ZY; Wang YW; Liu TT; Chen WX; Wu JJ; Xu WQ; Zhu P; Zhang BX J Cell Physiol; 2019 Jul; 234(7):11942-11950. PubMed ID: 30536816 [TBL] [Abstract][Full Text] [Related]
44. Mining Prognostic Biomarkers of Hepatocellular Carcinoma Based on Immune-Associated Genes. Chen W; Tang D; Ou M; Dai Y DNA Cell Biol; 2020 Apr; 39(4):499-512. PubMed ID: 32069130 [TBL] [Abstract][Full Text] [Related]
45. Identification of molecular subtypes and prognostic signature for hepatocellular carcinoma based on genes associated with homologous recombination deficiency. Lin H; Xie Y; Kong Y; Yang L; Li M Sci Rep; 2021 Dec; 11(1):24022. PubMed ID: 34912005 [TBL] [Abstract][Full Text] [Related]
46. Development of a Predictive Immune-Related Gene Signature Associated With Hepatocellular Carcinoma Patient Prognosis. Lei J; Zhang D; Yao C; Ding S; Lu Z Cancer Control; 2020; 27(1):1073274820977114. PubMed ID: 33269615 [TBL] [Abstract][Full Text] [Related]
47. Prediction of disease-free survival in hepatocellular carcinoma by gene expression profiling. Lim HY; Sohn I; Deng S; Lee J; Jung SH; Mao M; Xu J; Wang K; Shi S; Joh JW; Choi YL; Park CK Ann Surg Oncol; 2013 Nov; 20(12):3747-53. PubMed ID: 23800896 [TBL] [Abstract][Full Text] [Related]
48. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis. Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703 [TBL] [Abstract][Full Text] [Related]
49. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma. Zhang D; Duan Y; Wang Z; Lin J Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577 [TBL] [Abstract][Full Text] [Related]
50. Down-regulation of long non-coding RNA GAS5-AS1 and its prognostic and diagnostic significance in hepatocellular carcinoma. Wang Y; Jing W; Ma W; Liang C; Chai H; Tu J Cancer Biomark; 2018; 22(2):227-236. PubMed ID: 29660898 [TBL] [Abstract][Full Text] [Related]
51. Integrated analysis of competing endogenous RNA network revealing potential prognostic biomarkers of hepatocellular carcinoma. Liao X; Wang X; Huang K; Han C; Deng J; Yu T; Yang C; Huang R; Liu X; Yu L; Zhu G; Su H; Qin W; Zeng X; Han B; Han Q; Liu Z; Zhou X; Gong Y; Liu Z; Huang J; Winkler CA; O'Brien SJ; Ye X; Peng T J Cancer; 2019; 10(14):3267-3283. PubMed ID: 31289599 [No Abstract] [Full Text] [Related]
52. Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma. Chen QF; Li W; Wu PH; Shen LJ; Huang ZL World J Gastroenterol; 2019 Sep; 25(35):5266-5282. PubMed ID: 31558872 [TBL] [Abstract][Full Text] [Related]
53. A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma. Sun XY; Yu SZ; Zhang HP; Li J; Guo WZ; Zhang SJ Cancer Med; 2020 Apr; 9(8):2868-2878. PubMed ID: 32068352 [TBL] [Abstract][Full Text] [Related]
54. Development and validation of a m Kong W; Li X; Xu H; Gao Y Biomark Med; 2020 Sep; 14(13):1217-1228. PubMed ID: 33021385 [No Abstract] [Full Text] [Related]
55. A novel immune signature to predict the prognosis of patients with hepatocellular carcinoma. Li Q; Fan B; Ding J; Xiang X; Zhang J Medicine (Baltimore); 2021 Aug; 100(33):e26948. PubMed ID: 34414957 [TBL] [Abstract][Full Text] [Related]
57. A six-gene-based prognostic signature for hepatocellular carcinoma overall survival prediction. Wang Z; Teng D; Li Y; Hu Z; Liu L; Zheng H Life Sci; 2018 Jun; 203():83-91. PubMed ID: 29678742 [TBL] [Abstract][Full Text] [Related]
58. Gene signature to predict prognostic survival of hepatocellular carcinoma. Li L; Cao Y; Fan Y; Li R Open Med (Wars); 2022; 17(1):135-150. PubMed ID: 35071775 [TBL] [Abstract][Full Text] [Related]
59. Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. Tian MX; Liu WR; Wang H; Zhou YF; Jin L; Jiang XF; Tao CY; Tang Z; Zhou PY; Fang Y; Qu WF; Ding ZB; Peng YF; Dai Z; Qiu SJ; Zhou J; Lau WY; Fan J; Shi YH BMC Med; 2019 Jun; 17(1):106. PubMed ID: 31164128 [TBL] [Abstract][Full Text] [Related]
60. High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma. Guan Z; Cheng W; Huang D; Wei A Curr Res Transl Med; 2018 Mar; 66(1):27-32. PubMed ID: 29274707 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]